Market closedNon-fractionalADR
Burning Rock Biotech/BNR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Burning Rock Biotech
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Ticker
BNR
Sector
Healthcare
Trading on
NASDAQ
Industry
Healthcare Facilities
Headquarters
Guangzhou, China
Employees
786
Website
www.brbiotech.com
BNR Metrics
BasicAdvanced
$73M
Market cap
-
P/E ratio
-$64.81
EPS
0.18
Beta
-
Dividend rate
Price and volume
Market cap
$73M
Beta
0.18
52-week high
$26.20
52-week low
$5.72
Average daily volume
0.1
Financial strength
Current ratio
3.292
Quick ratio
3.045
Management effectiveness
Return on assets (TTM)
-49.12%
Return on equity (TTM)
-66.95%
Return on investment (TTM)
-65.97%
Valuation
Price to revenue (TTM)
1.02
Price to book
0.74
Price to tangible book (TTM)
0.742
Growth
Revenue change (TTM)
-8.71%
Earnings per share change (TTM)
45.74%
3-year revenue growth (CAGR)
7.73%
BNR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
¥126M
3.80%
Net income
-¥122M
-25.09%
Profit margin
-96.73%
-27.83%
BNR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Burning Rock Biotech stock?
Burning Rock Biotech (BNR) has a market cap of $73M as of July 27, 2024.
What is the P/E ratio for Burning Rock Biotech stock?
The price to earnings (P/E) ratio for Burning Rock Biotech (BNR) stock is 0 as of July 27, 2024.
Does Burning Rock Biotech stock pay dividends?
No, Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Burning Rock Biotech dividend payment date?
Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders.
What is the beta indicator for Burning Rock Biotech?
Burning Rock Biotech (BNR) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Burning Rock Biotech stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.